Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
2.176
-0.154 (-6.63%)
Nov 4, 2025, 2:56 PM EST - Market open
Acrivon Therapeutics Employees
As of December 31, 2024, Acrivon Therapeutics had 78 total employees, including 75 full-time and 3 part-time employees. The number of employees increased by 17 or 27.87% compared to the previous year.
Employees
78
Change (1Y)
17
Growth (1Y)
27.87%
Revenue / Employee
n/a
Profits / Employee
-$1,102,026
Market Cap
68.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 78 | 17 | 27.87% |
| Dec 31, 2023 | 61 | 17 | 38.64% |
| Dec 31, 2022 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACRV News
- 12 days ago - Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference - GlobeNewsWire
- 4 weeks ago - Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 6 months ago - Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 6 months ago - Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 - GlobeNewsWire
- 7 months ago - Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer - GlobeNewsWire
- 7 months ago - Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 8 months ago - Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates - GlobeNewsWire